JPRN-jRCT2080221139未知2 期
A Phase II/III, Randomized, Double-Blind, Parallel-Group Study to Assess the Safety and Immunogenicity of Intramuscular A-04-01D (H5N1 influenza vaccine) in Healthy Adult Japanese Volunteers
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 64age old（—）
- 性别
- All
入选标准
- •Healthy volunteers
排除标准
- •Known history of H5N1 influenza or received H5N1 influenza vaccination in the past.
研究者
相似试验
进行中（未招募）
不适用
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (25 mg qd and 50 mg qd) in Subjects with Symptoms of Overactive Bladder - CAPRICORSymptoms of overactive bladderEUCTR2008-007087-42-CZAstellas Pharma Europe B.V.1,300
进行中（未招募）
不适用
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (25 mg qd and 50 mg qd) in Subjects with Symptoms of Overactive Bladder - CAPRICORSymptoms of overactive bladderEUCTR2008-007087-42-PTAstellas Pharma Europe B.V.1,300
进行中（未招募）
不适用
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (25 mg qd and 50 mg qd) in Subjects with Symptoms of Overactive Bladder - CAPRICORSymptoms of overactive bladderEUCTR2008-007087-42-DEAstellas Pharma Europe B.V.1,800
进行中（未招募）
不适用
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (25 mg qd and 50 mg qd) in Subjects with Symptoms of Overactive Bladder - CAPRICOREUCTR2008-007087-42-FIAstellas Pharma Europe B.V.1,300
进行中（未招募）
不适用
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (25 mg qd and 50 mg qd) in Subjects with Symptoms of Overactive Bladder - CAPRICORSymptoms of overactive bladderEUCTR2008-007087-42-HUAstellas Pharma Europe B.V.1,300